Vericel's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Vericel's ROA in the second quarter of 2026?
Vericel Corporation achieved a return on average assets (ROA) of 5.04 % in its second quarter of 2026, this is above VCEL's average return on assets of -36.19%.
Vericel Corporation assets over the 12 months ending in its second quarter of 2026 are valued at $480 million

ROA has improved compared to 4.61% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 154 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 1254, from total ROA ranking in the first quarter of 2026 at 1697.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	13.56 %	25.34 %	34.09 %	48.81 %	43.52 %
Y / Y Net Income Change	-	-	17.35 %	-	-
Net Income (TTM) in million	24	21	17	13	7
Return On Assets (TTM)	5.04 %	4.61 %	3.74 %	3.19 %	1.91 %
VCEL's Total Ranking	# 1254	# 1697	# 1601	# 1924	# 2312
Total Assets (TTM) in million	495	486	488	453	436
Seq. Total Assets Change	1.86 %	-0.48 %	7.65 %	4.06 %	12.43 %
Seq. Net Income Change	-	-	358.08 %	-	-

VCEL's 5 Years Annual ROA >> Back to VCEL Management Effectiveness >> Compare VCEL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 16
Sector	# 155
Overall	# 1165

Return On Assets Statistics
High	Average	Low
5.02 %	-36.19 %	-174.75 %
(Jun 30 2026)		(Sep 30 2013)

Financial Statements
Vericel's Assets	$ 495 million	VCEL's Balance sheet
Vericel's Income	$ 2 million	Quarterly VCEL's Income Statement
VCEL's Income by Division		See VCEL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	50.96 %	29.14 %	20.25 %	17.66 %	27.94 %
Total Assets in million	549	364	282	234	199
Y / Y Net Income Change	59.41 %	-	-	-	-
Net Income in million	17	10	-3	-17	-7
Annual Return On Assets	3.01 %	2.85 %	-1.13 %	-7.13 %	-3.75 %

VCEL's 5 Years Annual ROA >> Back to VCEL Management Effectiveness >> Compare VCEL ROA to its Competitors

Comment on VCEL's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 3.01 % compared to prior year, due to annual net income growth of 59.41 % to $16.52 million, while value of Vericel's overall assets grew just by 50.96 % to $549.36 million, compared to $549.36 a year before.

More Return On Assets Ratios
VCEL's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VCEL's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VCEL's Competitors
Subscribers only: Roa for Vericel's Suppliers
Subscribers only: Return On Assets for VCEL's Customers

You may also want to know
VCEL's Roi	VCEL's Inventory Turnover Ratio	VCEL's Growth Rates	VCEL's Dividend Comparisons
	VCEL's Profitability Ratios	VCEL's Asset Turnover Ratio	VCEL's Dividend Growth
VCEL's Roe	VCEL's Valuation Ratios	VCEL's Financial Strength Ratios	VCEL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %
Illumina Inc	12.68 %
Spero Therapeutics Inc	12.57 %
Transmedics Group Inc	12.50 %
Eton Pharmaceuticals Inc	12.37 %
Nephros Inc	12.30 %
Msa Safety Inc	12.23 %
Strata Critical Medical Inc	12.18 %
Insulet Corporation	12.13 %
Lantheus Holdings Inc	11.89 %
Ligand Pharmaceuticals Incorporated	11.68 %
Theravance Biopharma inc	11.68 %
Carlisle Companies Incorporated	11.62 %
Encompass Health Corporation	11.60 %
Protagonist Therapeutics inc	11.02 %
Agilent Technologies inc	10.97 %
Prestige Consumer Healthcare Inc	10.90 %
Lemaitre Vascular Inc	10.90 %
Ufp Technologies Inc	10.85 %
Progyny Inc	10.66 %
Regeneron Pharmaceuticals Inc	10.60 %
Johnson and Johnson	10.60 %
Tenet Healthcare Corp	10.49 %
Bristol myers Squibb Company	10.27 %
Solventum Corporation	10.13 %

Date modified: 2026-09-12T19:01:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.